Ranbaxy Laboratories Limited's recent approval from the U.S. Food and Drug Administration will allow the pharmaceutical giant to sell generic versions of blood pressure drug Diovan.

Ranbaxy was originally supposed to produce the Novartis AG-owned medication in 2012, but the FDA prohibited the Indian production plant from sending the product to the U.S., according to The Financial Express. Employees reportedly worked in unsanitary conditions and forged quality tests on products, Bloomberg reported.

The company will now make 40, 80, 160, and 320mg capsules of the Valsartan medicine at Ranbaxy's New Jersey subsidiary Ohm Laboratory Limited plant. The building is the company's sole operating plant that can produce the medication for United States markets.

"The Office of Generic Drugs, USFDA, has determined the Ohm formulation to be bio-equivalent and have the same therapeutic effect as that of the branded drug Diovan," the company stated.

"Ohm is pleased to announce this first-to-file FDA approval for Valsartan tablets, which will be introduced to all classes of trade, with 180-days marketing exclusivity, as soon as sufficient supplies are manufactured to meet the needs of the market," added Bill Winter Ohm Laboratories Vice President, Sales and Distribution, North America.

Ranbaxy's alert on the company's Mohali plant in Punjab are included in their measures to prevent other law-violating plants from operating in subpar conditions. Employees reportedly breached standards while making products, according to Zeenews.

The FDA placed an import alert on the company's Mohali plant in Punjab in Sept 2013. Ranbaxy's Paonta Sahib facility in Himachal Pradesh, India, and the Dewas property in the Madhya Pradesh Indian state are also under close watch, according to company officials. The monitoring dates back to 2008.

The company pleaded guilty to felony charges in May 2013 concerning a case that dealt with products manufacturing and shipment issues.